Tumor Necrosis Factor-α Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow Transplantation in Children: A Pediatric Blood and Marrow Transplant Consortium Study  by Goyal, Rakesh K. et al.
CLINICAL RESEARCHFrom the 1
burgh
gram,
Penns
burgh
Bone
Colum
of Hu
sity o
Biosta
NY; 7
of Mi
igan;Tumor Necrosis Factor-a Gene Polymorphisms Are
Associated with Severity of Acute Graft-Versus-Host
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Marrow Transplantation in Children: A Pediatric Blood
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Rakesh K. Goyal,1,2 Yan Lin,3 Kirk R. Schultz,4 Robert E. Ferrell,5 Yeonhee Kim,3
Liane Fairfull,5 Elayne Livote,6 Gregory Yanik,7 Mark Atlas8Tumor necrosis factor (TNF)-a plays a significant role in conditioning related toxicities and the develop-
ment of acute graft-versus-host disease (aGVHD). TNF-a gene polymorphisms are associated with rejec-
tion after organ transplantation and aGVHD in matched related donor blood and marrow transplantation
(BMT) recipients. Few studies have been published on unrelated donor BMT in the pediatric age group. In
this study, we examined the relationship between specific polymorphisms in TNF pathway genes and the
occurrence and severity of aGVHD. Recipient single-nucleotide polymorphisms (SNPs) in TNF-a and TNF
receptor superfamily members 1A (TNFRSF1A) and 1B (TNFRSF1B) were investigated. In a multi-
institutional Pediatric Blood and Marrow Transplant Consortium trial, a total of 180 pediatric patients
(mean age, 11.0 years) were prospectively evaluated for clinical outcomes after matched unrelated donor
BMT. All patients received myeloablative conditioning and two-drug GVHD prophylaxis with cyclosporine
or tacrolimus, with methotrexate in the majority of patients. TNF-a genotypes were not correlated with
the overall incidence of aGVHD. Significant associations were seen between TNF-a variant alleles and the
severity of aGVHD (grade II-IV and grade III-IV), especially when analyzed in whites only (n 5 165).
Grade II-IV aGVHD was correlated with recipient -857T allele (hazard ratio [HR], 0.47; P 5 .04), -238A
allele (HR, 1.76; P 5 .002), and d3/d3 genotype (HR, 0.64; P 5 .03). Severe (grade III-IV) aGVHD was as-
sociated with TNF-a -1031C allele (HR, 2.38; P 5 .03), -863A allele (HR, 3.18; P 5 .003), and d4/d4 ge-
notype (HR, 2.82; P5 .01). After adjusting for clinical factors, the association of -1031C, -863A, -238A, and
d4/d4 genotypes with severity of aGVHD remained statistically significant. No correlation between se-
lected SNPs in TNFRSF1A or TNFRSF1B and the incidence or severity of aGVHD was found. Our findings
indicate clinically important relationships between genetic polymorphisms in TNF-a and the severity of
aGVHD in this cohort. Improved understanding of this relationship may allow for a risk-adjusted approach
to GVHD prevention in pediatric BMT.
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Allogeneic blood and marrow transplantation
(allo-BMT) from volunteer unrelated donors can
cure children with malignant and nonmalignant hema-
tologic diseases who lack a suitable family member
donor. Despite optimal supportive care and allele-
level HLA matching, acute graft-versus-host disease
(aGVHD) remains a major barrier to the success of
unrelated donor allo-BMT, necessitating immune
suppression and leading to chronic illness and
transplantation-related morbidity [1].
The pathophysiology of GVHD involves complex
interactions between cellular immune effectors, such
as donor T cells and host antigen-presenting cells, and
soluble effectors, such as inflammatory cytokines. The
role of tumor necrosis factor (TNF)-a as a critical
cytokine mediator of GVHD has been demonstrated
in murine models and in patients undergoing allo-
BMT [2-4]. Recipient TNF-a serum level during
pretransplantation conditioning has been correlated
with severe complications, aGVHD, and mortality.
Significant increases in TNF-a level have been
demonstrated in the first week posttransplantation,
correlating with increased severity of aGVHD. Recent
evidence also suggests that inhibition of TNF-a may
be beneficial as a primary treatment for aGVHD as
well as for steroid-refractory aGVHD [5,6].
TNF-a is a multifunctional proinflammatory cyto-
kine produced mainly by monocytes and macrophages
that up-regulates adhesion and major histocompatability
complex (MHC) molecule expression and can directly in-
duce cell death during the effector phase of aGVHD.
The gene encoding TNF-a is highly polymorphic and
located within the class III region of the MHC on chro-
mosome 6, close to the HLA region, lymphotoxin, and
heat-shock protein genes [7]. Polymorphisms in TNF-
a region genes have been associated with clinical out-
comes after organ transplantation and matched related
donor BMT [8,9]. Few studies of unrelated donor BMT
have been undertaken, however, especially in the
pediatric agegroup, and thepublisheddataareconflicting.
In the present study, we sought to examine
whether specific polymorphisms in TNF-a and the
TNF receptor superfamily member 1A (TNFRSF1A)
and 1B (TNFRSF1B) genes were correlated with
aGVHD incidence and severity, early toxic mortality,
and survival in a cohort of 180 pediatric patients
undergoing unrelated donor transplantation following
ablative conditioning and cyclosporine (CsA)- or
tacrolimus-based GVHD prophylaxis.
PATIENTS AND METHODS
Patients and Transplants
This study was approved by the Pediatric Blood
and Marrow Transplant Consortium (PBMTC)scientific committee, the National Marrow Donor
Program (NMDP) scientific committee and institu-
tional review board, and the institutional review
boards of the sponsoring institution (North Shore
LIJ Health System) and each participating institution,
and was monitored by the PBMTC Data Safety Mon-
itoring Committee. Informed consent was obtained
from all patients and donors or their legal guardians,
in accordance with the Declaration of Helsinki. Eligi-
bility criteria included age\21 years, matching based
on NMDP criteria (the donor must be a genotypic
match by intermediate resolution molecular typing of
HLA-A and -B and high-resolution molecular typing
for -DRb1 loci), myeloablative conditioning, and
GVHD prophylaxis with CsA or tacrolimus. Patients
receiving a T cell–depleted transplant, a cord blood
transplant, or reduced-intensity conditioning were in-
eligible. AGVHD and chronic GVHD were diagnosed
and graded according to standard criteria [10,11].
Clinical data were collected pretransplantation and at
180 days, 1 year, and 2 years posttransplantation
using standardized study forms and International
Blood and Marrow Transplant Registry GVHD data
inserts. Additional data were obtained from the
NDMP. Transplantation outcomes were reviewed by
a single investigator (M.A.), and any discrepancies
were resolved by chart review.Genotyping of Clinical Specimens
Pretransplantation recipient whole blood samples
collected by participating transplant centers in ACD
yellow-top tubes were sent by overnight courier at
room temperature to the University of Pittsburgh,
where they were cryopreserved as mononuclear cell
pellets. DNA extractions were performed in batches
using standard methods. Gene polymorphisms in
TNF-a, TNFRSF1A, and TNFRSF1B were exam-
ined. Single nucleotide polymorphisms (SNPs) with
a minor allele frequency of .5% (10 in all) and the
TNFd microsatellite were selected.
Genotyping of informative SNPs was performed by
polymerase chain reaction (PCR) amplification with
appropriate positive controls, with genotypes con-
firmed by DNA sequencing and negative controls (no
template) (Table 1). The PCR products were analyzed
using an ABI 3730 automated sequencer (Applied
Biosystems, Foster City, CA), and the sequences were
aligned and curated using Sequencher version 4.6
(Gene Codes Corporation, Ann Arbor, MI). Genotypes
were reviewed by 2 readers, and any disagreements were
resolved by consensus or by regenotyping. Alternative
genotyping methods are routinely available in our
laboratory, including fluorescence polarization, oligo-
nucleotide ligation assay, 50-nuclease assay, and pyrose-
quencing. Refer to the Supplement for additional
details.
Table 1. Oligonucleotide Primer Sequences
Polymorphism Forward Primer Reverse Primer
TNFd 50-FAM-CAT AGT GGG ACT CTG TCT
CAA AA-30
50-AGA TCC TTC CCT GTG AGT TCT GCT-30
TNF-a SNP set (-168 G>A to -1031 T>C) 50-CTC AGA GAG CTT CAG GGA-30 50-GAG AAA CCC ATG AGC TCA-30
TNFRSF1A SNP set (36 A>G to -609 G>T) 50-GAC TAG GAG GCTAGT GAA G-30 50-CTG AGG TTA GGA CCT GCA A-30
TNFRSF1B SNP set (1663 G>A to 1862 C>A) 50-CAG TTA ACC AGG CCG GTG-30 50-GGT TTT CTG GAA GCC AGA G-30
TNFRSF1B 676 T>G 50-CGT CAC TCT CCTATC CTG CCT G-30 50-CTT ACC AAC TGG AAG AGC GAA GTC-30
TNF indicates tumor necrosis factor; SNP, single nucleotide polymorphisms; TNFRSFI, TNF receptor superfamily members.
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Statistical analyses were performed by Y.L. using
SAS 9.1.3 (SAS Institute, Cary, NC) and R 2.7.2
(The R Project for Statistical Computing; www.r-
project.org). Cumulative incidence rates of aGVHD,
death in remission by day 100 (early treatment-
related mortality [TRM]), and overall survival (OS)
were estimated according to the method of Gray
[12]. Death before day1100 posttransplantation with-
out aGVHD was the competing risk for aGVHD.
Competing-risk analysis was conducted using the
cmprsk package in R. The k-sample test of Gray [12]
was used in univariate analysis of association between
clinical variables and the cumulative incidence of
aGVHD, early TRM, and OS. The 2-sided score sta-
tistics were used to test the hazard ratio (HR) for the
risk of aGVHD between the minor allele carrier and
noncarrier for each SNP. A P value of #.05 was
considered statistically significant. For multivariate
analysis, any clinical risk factor with a P value of
#.10 on univariate analysis was considered a potential
confounder. The proportional hazards model of Fine
and Gray [13] was used in the multivariate analysis of
association between individual SNPs and the risk of
aGVHD. No adjustments were made for multiple
comparisons, because we did not want to discard asso-
ciations that might be biologically relevant. Haplotype
analysis was carried out using the proc haplotype pro-
cedure in the SAS genetics package. The EM algo-
rithm was used to estimate haplotype frequencies,
and Fisher’s exact test was used to test associations be-
tween each haplotype and the risk of aGVHD [14-16].RESULTS
Patient Characteristics
Between April 27, 2002 and October 15, 2007, a to-
tal of 180 patients undergoing unrelated donor allo-
BMT at 29 institutions in the United States, Canada,
and New Zealand (Table 2) were enrolled. Of these pa-
tients, 165 (92%) were white, 7 were Asian, 5 were
black, 2 were American Indian and 1 of unknown
race/ethnicity. All of the recipient–donor pairs were
matched at the allele level for HLA-DRb1 loci and at
the antigen level for HLA-A and HLA-B loci. Allele-
level typing was available for HLA-A and HLA-Bloci for 152 of 180 transplants; 142 of 152 recipient–
donor pairs were allele-matched, whereas 10 of 152
had mismatches (single A allele, n 5 5; two A alleles,
n 5 1; single B allele, n 5 2; A and B alleles, n 5 2).
All patients underwent myeloablative conditioning
and received unmanipulated grafts containing T cells.
The cumulative incidence of aGVHD (all grades)
by day 1100 was 60.0% (95% confidence interval
[CI], 52.8%-67.2%), that of grade II-IV aGVHD
was 44.5% (95% CI, 37.2%-51.8%), and that of grade
III-IV aGVHD was 17.8% (95% CI, 12.2%-23.4%).
aGVHD was diagnosed before day 1100 in 108/115
cases (94%). The distribution of maximal overall grade
was 30 grade I (26%), 49 grade II (43%), 26 grade III
(22%), and 10 grade IV (9%).
Univariate and multivariate models were used to
identify independent risk factors for aGVHD, early
TRM, and OS (Table 3). Ninety-eight of 145 patients
(67.58%) with malignant diseases developed aGVHD,
versus 17 of 35 (48.57%) with nonmalignant diseases
(HR, 1.767; 95% CI, 1.070-2.917; P5 .026). No other
clinical factor examined was significantly associated
with incidence of aGVHD.
TNF Genotypes
The observed genotype and allele frequencies for
investigated SNPs were similar to those reported in
the literature and cataloged in dbSNP (www.ncbi.nlm.
nih.gov/projects/SNP/). (See Supplement Table 1 for
genotype and allele frequencies.) With only 2 excep-
tions, the genotype distributions were in Hardy-
Weinberg equilibrium. The distributions of
TNFRSF1A-609 G.T and TNFRSF1B-676 T.G
did not meet the requirements for Hardy-Weinberg
equilibrium, possibly reflecting racial admixture of
the population. Genotyping was verified using 2
methods (restriction fragment length polymorphism
and sequencing), making genotyping error less likely.
Correlation of TNF-a and TNF Receptor
Genotypes with the Incidence and Severity
of aGVHD
The cumulative incidence of aGVHD (grade I-IV)
and the severity of aGVHD (grade II-IV and grade III-
IV) were correlated with TNF genotype. Association
studies of unrelated individuals of different ethnicity
or race can confound the comparisons between case
Table 2. Patient and Transplant Characteristics
Characteristic
Number
of Patients Number, Average, Range
Total number of patients 180
Patient age at transplantation 180 Mean, 11.0; median, 12.1; range, 0.5-20.7
Sex
Recipient 180 Males, 105; females, 75
Donor 178 Males, 110; females, 68
Race
Recipient 179 Whites, 165; other, 14
Donor 145 Whites, 112; other, 33
Indication for transplantation 180
Leukemia or myelodysplastic syndrome 134
Other malignancies 11
Nonmalignant 35
Conditioning regimen 180
Busulfan-based Yes, 63; no, 117
Total body irradiation Yes, 112, no, 68
GVHD prophylaxis 180
Cyclosporine-based 115
Tacrolimus-based 65
GVHD prophylaxis with methotrexate as second agent 180 Yes, 164; no, 16
Antithymocyte globulin 180 Yes, 50; no, 130
Stem cell source 180
Bone marrow 119
Peripheral blood 61
HLA
A and B loci antigen match and DRb allele match 180 180
A and B loci allele match 152 Match, 142; mismatch, 10
aGVHD 180 Yes, 115; no, 65
aGVHD by day 100 115 Yes, 108; no, 7
aGVHD maximal overall grade 115 Grade I, 30; II, 49; III, 26; IV, 10
Competing risk: death by day +100 without aGVHD 180 Yes, 16; no, 164
Cumulative incidence of grade I-IV aGVHD at day +100 60.0% (95% CI: 52.8%-67.2%)
Cumulative incidence of grade II-IV aGVHD at day +100 44.5% (95% CI: 37.2%-51.8%)
Cumulative Incidence of grade III-IV aGVHD at day +100 17.8% (95% CI, 12.2%-23.4%)
Death in remission at day +100 (early TRM) 180 Yes, 17; no, 163
Cumulative incidence of death in remission at day +100 (early TRM) 180 8.9% (95% CI, 5.6%-14.2%)
Chronic GVHD 178 Yes, 78; no, 77; not evaluable (died before day +100), 23
Chronic GVHD stage 76 Limited, 16; extensive, 60
Survival status 180 Alive, 107; dead ,73
OS 1 year: 66.5% (95% CI: 59.4%-73.5%)
2 years: 56.7% (95% CI: 48.8-64.5%) (median follow-up, 458 days)
GVHD indicates graft-versus-host disease; aGVHD, acute graft-versus-host disease; OS, overall survival.
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tions (population stratification) [17]. To address this
issue, aGVHD outcomes were correlated with TNF
genotypes for the entire cohort (n 5 180), as well as
for whites only (n5 165). Because of the limited num-
bers and different ethnicities, non-white patients were
not analyzed separately. Clinical covariates BMT indi-
cation (malignant vs. nonmalignant) and GVHD pro-
phylaxis (CsA vs. tacrolimus) achieved p value #0.1
and were included in multivariate modeling.
No significant correlation was found between
TNF-a gene polymorphisms and the incidence of
aGVHD (grade I-IV). In addition, no associations be-
tween TNFRSF1A and TNFRSF1B SNPs and the in-
cidence or severity of aGVHD were noted. Significant
associations were observed between the TNF-a variant
alleles and the severity of a GVHD (grade II-IV and
grade III-IV) (Table 4 and Figure 1). For the entire
group, there was a higher risk of severe aGVHD in pa-
tients with the TNF-a d4/d4 genotype (HR, 2.34; P5
.03) and the -238A variant allele (HR 1.76; P 5 .002).In whites, besides these sites, significant associations
were observed with other TNF-a gene polymor-
phisms. The risk of grade III-IV aGVHD was greater
in recipients with the TNF-a -1031C allele (HR, 2.38;
P5 .03), -863A allele (HR, 3.18; P5 .003), and d4/d4
genotype (HR 2.82; P 5 .01). Patients with the -238A
allele were at greater risk for grade II-IV aGVHD
(HR, 1.76; P 5 .002). These associations remained
statistically significant after multivariate analysis. In
contrast, the risk of grade II-IV aGVHD was lower
in patients with the -857T allele (HR, 0.47; P 5 .04)
and the d3/d3 genotype (HR, 0.64; P 5 .03).
The minor allele frequency for -308 G.A was
0.02, and our study was underpowered to assess the
potential contribution of -308 G.A to the risk of
aGVHD (data not shown).
Association between TNF-a Haplotype and the
Incidence and Severity of aGVHD
Haplotype frequencies were calculated in the 165
white subjects. Four TNF-a promoter region SNPs
Table 3. Association of Clinical Variables and Risk of aGVHD
With aGVHD, n (%) Without aGVHD, n (%) Total Univariate P Value HR (95% CI)
Number of study subjects 115 (63.89) 65 (36.11) 180
Sex
Female 46 (61.33) 29 (38.67) 75 .790 0.949 (0.649-1.387)
Male 69 (65.71) 36 (34.29) 105
Race/ethnicity
White 105 (63.64) 60 (36.36) 165 1.000 0.999 (0.546-1.830)
Others 9 (64.29) 5 (35.71) 14
Age at BMT, years
Mean (range) 11.11 (20.18) 10.86 (19.55) 180 .260 1.018 (0.987-1.051)
Median (range) 11.93 (20.18) 12.44 (19.55)
Indications for BMT
Leukemia or myelodysplastic syndrome 91 (67.91) 43 (32.09) 134 .026* 1.767 (1.070-2.917)*
Other malignancies 7 (63.64) 4 (36.36) 11
Nonmalignant 17 (48.57) 18 (51.43) 35
Stem cell source
Bone marrow 81 (68.07) 38 (31.93) 119 .290 1.255 (0.826-1.909)
Peripheral blood 34 (55.73) 27 (44.26) 61
Conditioning
Radiation-based 73 (65.18) 39 (34.82) 112 .160 1.324 (0.896-1.955)
Chemical 42 (61.76) 26 (38.24) 68
GVHD prophylaxis
Cyclosporine-based 68 (59.13) 47 (40.87) 115 .110 0.733 (0.502-1.069)
Tacrolimus-based 47 (72.31) 18 (27.69) 65
Antithymocyte globulin
Yes 29 (58.00) 21 (42.00) 50 .200 0.751 (0.483-1.168)
No 86 (66.15) 44 (33.85) 130
Duration of follow-up, days, median (range) 450 (28-2031) 499 (7-1681) 179 .730 1.000 (1.000-1.000)
BMT indicates bone marrow transplantation; GVHD, graft-versus-host disease.
*Leukemia and other malignancies versus nonmalignant diseases.
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were segregated as 5 distinct haplotypes with frequen-
cies of $6% (Table 5). Compared with the prevalent
haplotype T-C-C-G, patients with the T-C-C-A hap-
lotype had a 1.6-fold greater risk of grade II-IV
aGVHD, those with the C-A-C-G haplotype had
a 2.5-fold greater risk of grade III-IV aGVHD, and
those with the T-C-T-G haplotype had a 0.4-fold
lower risk of grade II-IV aGVHD.
Associations among TNF-a Polymorphism,
Early Toxic Mortality, and Survival
The cumulative incidence of death by day1100 in
remission was 8.9% (95% CI, 5.6%-14.2%). No sig-
nificant association was seen between the TNF-
a SNPs examined and the risk of early toxic mortality.
At a median follow-up of 1.25 years (range, 0.019-
19.10 years), 107 of 180 patients (59.4%) survived.
The 1-year OS was 66.5% (95% CI, 59.4%-73.5%),
and the 2-year OS was 56.7% (95% CI, 48.8%-
64.5%). No significant association was found between
the TNF-a SNPs examined and OS.DISCUSSION
Several previous studies have examined the rela-
tionship between TNF-a gene polymorphisms and
posttransplantation outcomes, such as aGVHD and
chronic GVHD, engraftment, early toxic mortality,and survival [8]. The current prospective study was
performed to investigate the relationship between cy-
tokine gene polymorphisms and the risk of aGVHD,
using a candidate gene approach in a pediatric patient
population undergoing matched unrelated donor
(MUD) transplantation. This article describes our re-
sults for recipient TNF-a genotypes, which corrobo-
rate and extend previously published results on the
severity of aGVHD with significant new findings.
Gene association studies conventionally require a test
of association confirmed in at least one additional in-
dependent cohort. We effectively accounted for this
requirement by testing hypotheses published in similar
previous studies of BMT.
In the present study, recipient TNF-a genotypes
for a number of promoter polymorphisms, including
-1031C, -863A, -857T, -308A, and -238A variant al-
leles, as well as d3/d3 and d4/d4 microsatellite alleles,
were examined. The prognostic importance of each of
these variant alleles is conflicting in the literature, with
study results depending on the size and demographics
of the patient population and relative frequency of
the minor alleles investigated [7,18-27]. In contrast
to those studies, our patient population did not
represent the experience from a single transplant
center. Instead, data were collected prospectively
on patients from more than 20 transplant centers
within the PBMTC, with each patient receiving CsA
or tacrolimus, plus methotrexate, for GVHD
prophylaxis.
Table 4. Incidence of aGVHD (I-IV) and Severity of aGVHD (II-IV and III-IV) Correlated with TNF-a SNP Genotypes and
d Microsatellite
aGVHD Severity
TNF-a Genotype aGVHD Incidence (Grade I-IV) (Grade II-IV) (Grade III-IV)
-1031 T>C
CC/CT 39/62 (63%) 27/62 (44%) 14/62 (23%)
TT 66/114 (58%) 50/114 (44%) 16/114 (14%)
HR/P value 1.08/ 0.29 0.99/ 0.77 1.61/ 0.13
HR/P value (Whites only) 1.11/ 0.26 1.24/ 0.17 2.38/ 0.03
Adjusted HR/P (Whites only) 1.15/ 0.51 1.16/ 0.56 2.49/ 0.025
-863 C>A
AA/AC 23/43(54%) 15/43(37%) 11/43(26%)
CC 79/124(64%) 60/124(48%) 17/124(14%)
HR/P value 0.84/ 0.50 0.72/ 0.21 1.87/ 0.06
HR/P value (Whites only) 0.84/ 0.53 0.87/ 0.70 3.18/ 0.003
Adjusted HR/P (Whites only) 0.81/ 0.44 0.73/ 0.32 3.31/ 0.0069
-857 C>T
TT/TC 13/26(50%) 7/26(27%) 5/26(19%)
CC 89/141(63%) 68/141(48%) 23/141(16%)
HR/P value 0.79/ 0.29 0.56/ 0.06 1.18/ 0.73
HR/P value (Whites only) 0.81/ 0.38 0.47/ 0.04 0.92/ 0.87
Adjusted HR/P (Whites only) 0.70/ 0.26 0.45/ 0.085 1.20/ 0.74
-238 G>A
AA/AG 32/48(67%) 30/48(65%) 9/48(19%)
GG 70/120(58%) 45/120(38%) 19/120(16%)
HR/P value 1.15/ 0.28 1.67/0.002 1.18/0.63
HR/P value (Whites only) 1.19/ 0.16 1.76/ 0.002 0.82/ 0.73
Adjusted HR/P (Whites only) 1.52/ 0.066 2.38/0. 00079 1.38/ 0.46
d microsatellite
d3/d3 27/53(51%) 18/53(34%) 7/53(13%)
Non-d3/d3 80/125(64%) 61/125(49%) 25/125(20%)
HR/P value 0.80/ 0.11 0.70/0.07 0.66/0.28
HR/P value (Whites only) 0.78/ 0.10 0.64/ 0.03 0.48/ 0.13
Adjusted HR/P (Whites only) 0.69/ 0.10 0.58/ 0.055 0.49/ 0.15
d microsatellite
d4/d4 12/16(75%) 9/16(56%) 6/16(38%)
Non-d4/d4 95/162(59%) 70/162(43%) 26/162(16%)
HR/P value 1.06/ 0.71 1.30/0.26 2.34/0.03
HR/P value (Whites only) 1.14/ 0.37 1.31/ 0.29 2.82/ 0.01
Adjusted HR/P (Whites only) 1.52/ 0.19 1.61/ 0.18 3.06/ 0.016
TNF indicates tumor necrosis factor; SNP, single nucleotide polymorphisms; aGVHD. acute graft-versus-host disease.
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a correlation between the widely studied -308 G.A
polymorphism and the risk of aGVHD, with an asso-
ciation described in an initial study [27] but not in
other, larger studies [22,23,25,26,28]. Our study
lacked sufficient power to evaluate the association
between TNF-a -308 G.A SNP and the risk of
aGVHD.
Nordlander et al. [24], in a study of 111 MUD and
85 sibling donor transplantations, reported a greater
risk of grade II-IV aGVHD in recipients with the d4
allele in the sibling transplants, but not in the MUD
transplants. The TNFd4 allele was associated with
a greater risk of TRM, but not of aGVHD, in a study
of 182 patients undergoing MUD transplantation [21].
Bettens et al. [18], in a study of 131 MUD transplanta-
tions, found lower 3-year survival rates in patients with
the TNFd3/d3, d4, and d5 genotypes compared with
those with the TNFd1/d2/d3 genotype; that study
did not report on aGVHD outcome, however. In the
present study, we found a nearly 3-fold greater risk
of severe aGVHD in those with the d4/d4 genotype.Taken together, these data suggest that recipient
TNFd4 allele is associated with worse transplantation
outcome and merits further investigation as a marker
for the prospective identification of patients at high
risk of aGVHD and death.
The TNFd3 homozygous genotype was associated
with increased incidence of grade III-IV aGVHD in
the initial report of 49 patients undergoing matched
sibling transplantation with single-agent prophylaxis
with CsA [22]. This association was not confirmed in
subsequent studies of related or unrelated donor or
cord blood transplantations [19,24,29]. Our study
found a modest reduction in the risk of grade II-IV
aGVHD in those with the d3/d3 genotype versus those
with non-d3/d3 genotypes, but no difference in the
risk of severe aGVHD between the 2 groups.
We analyzed 4 TNF-a promoter region SNPs
individually and as a haplotype, and found a greater
risk of grade II-IV aGVHD with the recipient TNF-
a -238A allele, and of severe (grade III-IV) aGVHD
with the -1031C and -863A alleles. In contrast, the var-
iant TNF-a -857T allele was associated with a lower
Figure 1. Cumulative incidence of grade II-IV aGVHD (left panel) and grade III-IV aGVHD (right panel) according to TNF-a genotypes.
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haplotype analysis revealed that, compared with
patients with the prevalent T-C-C-G haplotype, those
with the T-C-C-A haplotype were at 1.5-fold greaterrisk of grade II-IV aGVHD, and those with the C-A-
C-G haplotype were at 2.5-fold greater risk of grade
III-IV aGVHD. Keen et al. [21] reported that the
-1031C allele and -1031C-d4 haplotype were
Table 5. Association of TNF-a 4 SNP Haplotype* and aGVHD Incidence and Severity in Whites
AGVHD Grade, HR (P value)
Haplotype Frequency 0 vs I-IV 0-I vs II-IV 0-II vs III-IV
T-C-C-G 0.56 0.94 (.57) 0.89 (.51) 0.64 (.23)
T-C-C-A 0.14 1.14 (.37) 1.59 (.004) 0.98 (.99)
C-A-C-G 0.13 0.95 (.74) 0.92 (.72) 2.48 (.002)
T-C-T-G 0.09 0.69 (.082) 0.39 (.014) 0.77 (.69)
C-C-C-G 0.06 1.63 (<.001) 1.39 (.18) 0.42 (.32)
TNF indicates tumor necrosis factor; SNP, single nucleotide polymorphisms; aGVHD, acute graft-versus-host disease.
*-1031 T>C, -863 C>A, -857 C>T, and -238 G>A.
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not with an increased risk of aGVHD. That study did
not examine other promoter region SNPs. We reana-
lyzed risk haplotypes after inclusion of the d4 allele and
found no difference from the significant associations
already observed with the 50 4 SNP promoter region
haplotype (data not shown), suggesting that the d4 al-
lele does not contribute to the at-risk haplotype in this
patient cohort, in contrast to what was reported by
Keen et al. [21]. Ishikawa et al. [20], in a study of Jap-
anese adult MUD transplantations, found a higher in-
cidence of grade III-IV aGVHD in patients with the
TNF-a 3 SNP (-1031, -863, -857) T-C-T or C-A-C
haplotypes compared with those with the T-C-C hap-
lotype. These authors did not examine promoter re-
gion SNPs individually.
Given the differences in how haplotypes were ana-
lyzed, findings from the 3 aforementioned studies are
not directly comparable; however, taken together,
our individual SNP findings and haplotype data sug-
gest that these TNF-a promoter region SNPs play
a role in differential risk of aGVHD severity. We be-
lieve that the haplotype is responsible for the observed
effects, because of the problem of assigning function to
SNPs in this region. The individual SNPs are associ-
ated because of the linkage disequilibrium between
them, as reflected in at-risk haplotypes.
The TNF-a gene is located on chromosome 6
within the class III region of the MHC complex, be-
tween the HLA class I and class II loci regions and
close to genes encoding other members of the TNF
superfamily, lymphotoxin a, lymphotoxin b, and
heat-shock protein 70. Because the TNF-a gene is in
strong linkage disequilibrium with a number of genes
involved in immune function, and because of the selec-
tion for this region, functional significance cannot be
assigned to any observed association [30,31]. In the
MUD transplant setting, unlike the HLA-matched
sibling setting, there is also the likelihood of minor his-
tocompatibility antigen and HLA-C locus mismatches
and a consequent impact on GVHD risk, which was
not evaluable in the present study. TNF-a and IL-10
locus polymorphisms not only are independent, but
also may be interacting in association with risk for
aGVHD [22,28]. But the present study was limited
to gene polymorphisms that might modulate theactivity of TNF-a biologically, and did not examine
potential interactions with structural variation in
other genes implicated in aGVHD pathogenesis.
As has been highlighted in recent studies [17,32],
various factors alone or in combination may account
for the differences in findings among previous studies,
including sample size, study power, population
heterogeneity (ie, age, ethnicity, diagnosis, and disease
stage), and transplant characteristics (ie, HLA match,
stem cell source, intensity of conditioning regimen,
GVHD prophylaxis, and T cell depletion). In some
studies, related and unrelated donor transplantations
were pooled and adjustments not made for relevant
clinical covariates. There also has been a lack of
consistency in correlative analyses both in terms of the
clinical endpoint (varying from aGVHD of any grade
[I-IV] to significant [grade II-IV] to severe [grade III-
IV]), and how genotypic information is used, especially
in the construction of haplotypes. This also may account
for, at least in part, the differences among studies, which
led us to examine both the incidence and severity of
aGVHD and report both positive and negative results.
The TNFRSF1B coding region SNP in exon 6 (676
T.G) results in nonconservative substitution (196
M.R), and the donor 196R allele was found to be
correlated with increased risk of severe aGVHD after
MUD transplantations [20]. In another study of adult
matched sibling BMT recipients, an increased
incidence of acute GVHD was observed in 196R recip-
ients [33]. TNFRSF1B 30-UTR gene polymorphisms
have been associated with differential reporter gene ex-
pression and clinical outcomes in nontransplantation
settings [34]. Our study found no association between
these candidate gene polymorphisms in TNFRSF1B
and the risk of aGVHD, early toxic mortality, or
survival.
Although it has been widely studied in single center
trials, the impact of cytokine gene polymorphisms has
yet to be considered prospectively in determining the
risk for aGVHD and transplantation morbidity/mortal-
ity. A combination of GVHD risk factors in pediatric
MUD transplantations could be considered in the
future, with TNF-a genotyping included in the analyses
along with HLA matching, donor age, ABO status, and
other clinical factors. It would be of interest to examine
relationship between TNF genotypes and response to
Biol Blood Marrow Transplant 16:927-936, 2010 935TNF-a Polymorphisms and Acute GVHDtreatment with TNF inhibitors, including anti-TNF an-
tibodies and soluble TNF-binding agents [6]. Risk strat-
ification based on TNF genotyping could be determined
before transplantation, with subsequent inclusion of
TNF inhibitors into the GVHD prophylaxis regimen
of high-risk patients. Ultimately, the development of
a GVHD risk-related score, based on cytokine gene
polymorphisms, should be considered, incorporating
assessment of variant alleles that may increase the rela-
tive risk of aGVHD (ie, TNF-a -1031C, -863A,
-238A, and d4/d4) and those that may decrease the risk
of aGVHD (ie, -857T and d3/d3) in white pediatric
transplantation recipients. Our correlative findings are
most robust for whites, and their potential significance
in nonwhites would require examination in separate
race/ethnicity-specific cohorts of sufficient size. The
generalizability of our results also is limited by the lack
of consideration of donor TNF-a genotypes.
In summary, in our cohort of pediatric MUD
transplantation recipients who underwent ablative
conditioning, we found significant associations
between multiple promoter region SNPs, the TNFd
microsatellite, and statistically inferred haplotypes in
the TNF-a gene with the severity of aGVHD. This re-
lationship held up on multivariate analyses and is likely
an independent risk factor. Our findings, along with
previous reports of an association with the severity of
aGVHD, suggest a pathogenic role for TNF-a alleles,
which may be of functional importance or may serve as
markers for linked genetic variants. These data require
further confirmation in independent cohorts;
increased understanding of this relationship may allow
for a risk-adjusted approach to GVHD prevention.PARTICIPATING PBMTC INSTITUTIONS
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Genotyping Methods
Whole Genome Amplification: Because of limited
amount of DNA available on some clinical specimens,
all samples were subjected to whole genome amplifica-
tion using the multiple displacement amplification pro-
tocolofDean,etal. (RepliGkit,QiagenInc.) [12].Upon
completion of the assay, all samples were diluted 1:100
with sterile distilled water and stored at -20C.
1. TNFd Allele Microsatellite: A region upstream of
the TNF-a gene, approximately 130 base pairs in
length and containing the d allele microsatellite
(TNFd) was amplified using the primers listed in
Table 1. Specifically, the final PCR reaction mix-
ture included 1X PCR buffer, 1.5 mM MgCl2,
0.2mM dNTP mix, 0.3mM fluorescent labeled for-
ward primer, 0.3mM reverse primer, 0.5U Taq
polymerase (all reagents from Invitrogen), and
2.0ml whole genome amplified, diluted DNA. The
final volume per reaction was 25ml. PCR conditions
were previously described [13]; briefly, initial dena-
turation step of 94C for 3 minutes followed by 30
cycles of 94C for 3 minutes (denaturation), 60C
for 1 minute (annealing), and 72C for 1 minute (ex-
tension).
2. TNF-a SNP Genotyping: A 960 base pair region of
the TNF-a 5’ upstream sequence from bp -1116 to
-20 was amplified using primers listed in Table 1.
The PCR reaction mixture included 2.0mM
MgCl2 but otherwise was same as described for
the TNFd microsatellite polymorphism. PCR con-
ditions were: 5 minute initial denaturation step at
95C followed by 35 cycles of 95C for 30 seconds
(denaturation), 52C for 30 seconds (annealing),
and 72C for 45 seconds (extension). There was
a final extension step for 5 minutes at 72C.
3. TNFRSF1A: A 960 base pair region 5’ of the
TNFRSF1A gene from bp -640 to +176 was ampli-
fied using the primers listed in Table 1. The PCR
reaction mixture included 2.0mM MgCl2 but oth-
erwise was the same as described for the TNFd mi-
crosatellite polymorphism. PCR conditions were: 5
minute initial denaturation step at 95C followed
by 35 cycles of 95C for 30 seconds (denaturation),
56C for 30 seconds (annealing), and 72C for 40
seconds (extension). There was a final extension
step for 5 minutes at 72C.4. TNFRSF1B: A 420 base pair region of the
TNFRSF1B gene in the 3’ untranslated region
(exon 10) was amplified using primers listed in
Table 1 using the PCR conditions for amplification
of the TNFd microsatellite. TNFRSF1B 676
(T.G) SNP was genotyped by the RFLP protocol
of Peral, et al [14].
Genotype and allele frequencies are shown in Supple-
mental Table 1.
Supplemental Table 1. Genotype andAllele Frequencies
Gene Site Genotypes Allele FrequenciesTNF-a -1031 T>C TT 114 (65%) T 80%
(rs1799964) CT 52 (29%) C 20%CC 10 (6%)-863 C>A CC 124 (74%) C 86%
(rs1800630) AC 39 (24%) A 14%AA 4 (2%)-857 C>T CC 141 (84%) C 91%
(rs1799724) CT 23 (14%) A 9%TT 3 (2%)-238 G>A GG 120 (72%) G 85%
(rs361525) GA 44 (26%) A 15%AA 4 (2%)d microsatellite d3/d3 53 (30%) d3 50%
non-d3/d3125 (70%) d4 27%d4/d4 16 (9%) d other 23%
non-d4/d4 162 (91%)TNFRSF1A -609 G>T GG 82 (47%) G 66%
(rs4149570) GT 65 (37%) T 34%TT 27 (16%)36 A>G AA 59 (34%) A 58%
(rs767455) AG 81 (47%) G 42%GG 32 (19%)TNFRSF1B 676 T>G TT 109 (62%) T 77%
(rs1061622) GT 51 (29%) G 23%GG 15 (9%)1663 G>A GG 52 (31%) G 55%
(rs1061624) GA 82 (49%) A 45%AA 35 (21%)1690 T>C TT 65 (38%) T 61%
(rs3397) CT 75 (44%) C 39%CC 29 (17%)1862 C>A CC 133 (81%) C 90%
none AC 29 (18%) A 10%AA 2 (1%)
